CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
When To Choose A Benchmark Over A Strategic Index explains decision points for selecting benchmarks based on goals, cost, and risk tolerance.
25,499 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A high-profile moment can ripple into personal finances. This piece examines the Tyson Paris Fury Face backlash, what...
Ripple merges Swell with XRPL Apex for its biggest New York conference yet, stitching together enterprise payments an...
When memory and storage costs rise, Apple often responds with price shifts. This article explains how those moves aff...
Axcelis Technologies has seen its stock surge this year, riding AI-chip demand. This guide breaks down what the compa...
Tech-focused investors watched TeraWulf surge after a major AI data-center lease deal, signaling potential recurring ...
Meta Platforms surged about 6% as traders embraced a leaner AI cloud plan. Analysts say the cost-cutting framework co...
NIO delivered a surprising Q4 2025 GAAP profit and outlined a 2026 path to positive non-GAAP earnings, supported by m...
A top financial executive recently disclosed a share sale at Robinhood. This article breaks down what the move means,...
A close look at on-chain data shows Vitalik Buterin holding roughly 240,000 ETH, with recent large withdrawals and a ...
Circle posted a surprising earnings beat as stablecoins attract ongoing demand, lifting circle shares and underscorin...
Two space-focused stocks surged on Tuesday as investors parsed earnings and broker calls, lifting AeroVironment and A...